Omalizumab-Facilitated Oral Immunotherapy with Direct Initiation at Maintenance Dosing for Most Foods.

Cohort studyAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology· Aug 2026

Omalizumab-Facilitated Oral Immunotherapy with Direct Initiation at Maintenance Dosing for Most Foods.

Colleen M Shannon, Katie L Kennedy, Juhee Lee … Antonella Cianferoni

Read paper

Allergy & ImmunologyCohort studyTreatmentQ2IF 3.2

Omalizumab pretreatment let 94% of food initiation challenges succeed at maintenance dosing.

Omalizumab-Facilitated Oral Immunotherapy with Direct Initiation at Maintenance Dosing for Most Foods.

Colleen M Shannon … Antonella Cianferoni

Annals of allergy, asthma & immunology · Aug 2026 · Q2 in Immunology & Allergy

Background

Existing clinical oral immunotherapy (oral immunotherapy) protocols require multistep initial dose escalations and frequent up-dosing visits.

Purpose

To characterize outcomes associated with an omalizumab-facilitated oral immunotherapy protocol designed to enable direct initiation at maintenance dosing for most foods.

Methods

We conducted a prospective cohort study of 100 children and young adults who initiated omalizumab-facilitated oral immunotherapy between July 2024 and October 2025.

n = 100 children

94%

Results

94%

omalizumab pretreatment let almost all challenges succeed at full maintenance dosing

n = 100 children

More results

Ninety-seven patients (97%) initiated daily dosing for at least one food and 81 (84%) started at target doses for all foods.

Two patients discontinued therapy due to adverse events.

Among those who met criteria for omalizumab discontinuation, median treatment duration was 26.3 weeks (IQR: 20.7 - 36.4).

“

Conclusion · 1 of 2

In this cohort, a short course of omalizumab facilitated direct initiation at maintenance dosing for most foods. Most patients successfully initiated therapy at target doses, and treatment discontinuation was uncommon.

Conclusion · 2 of 2

This approach may reduce treatment burden while maintaining an acceptable safety profile.

Omalizumab-Facilitated Oral Immunotherapy with Direct Initiation at Maintenance Dosing for Most Foods.

Omalizumab-Facilitated Oral Immunotherapy with Direct Initiation at Maintenance Dosing for Most Foods.

Related papers